NarendranathEpperlaMDMS

Oncology • Salt Lake City, UT

Hematologic Oncology

Associate Professor

Join to view full profile

Dr. Epperla is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Epperla's full profile

Already have an account?

Office
2000 Circle of Hope
Salt Lake City, UT 84112

Summary

Dr. Narendranath Epperla is an Associate Professor and Associate Chief of Clinical Research at Huntsman Cancer Institute, University of Utah.

Education & Training

Medical College of WisconsinMS, 2015 - 2017
Medical College of Wisconsin Affiliated HospitalsFellowship, Hematology and Medical Oncology, 2017
Marshfield ClinicResidency, Internal Medicine, 2010 - 2013
Kamineni Institute of Medical ScienceClass of 2007

Certifications & Licensure

UT State Medical License 2024 - 2026
OH State Medical License 2017 - 2025
WI State Medical License 2011 - 2017
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma Start of enrollment: 2021 May 24
Recruiting
Phase 1
Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin Lymphoma Start of enrollment: 2022 Jul 01
Withdrawn
Phase 1
Nanochip Technology in Monitoring Treatment Response and Detecting Relapse in Participants With Diffuse Large B-Cell Lymphoma Start of enrollment: 2018 Sep 26
Recruiting
Not Applicable
A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma Start of enrollment: 2023 Jan 26
Recruiting
Phase 1, Phase 2
Acalabrutinib and Durvalumab in Primary and Secondary Central Nervous System Lymphoma Start of enrollment: 2021 Apr 29
Recruiting
Phase 1
Pharmacogenomics Effects on High-Dose Methotrexate Clearance in Patients With Diffuse Large B-Cell Lymphoma Start of enrollment: 2023 May 10
Recruiting
Pemigatinib for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma or Marginal Zone Lymphoma Start of enrollment: 2024 Apr 30
Not yet recruiting
Phase 2
Pirtobrutinib With Rituximab for the Treatment of Newly Diagnosed Marginal Zone Lymphoma Start of enrollment: 2024 May 01
Not yet recruiting
Phase 2
Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery (SRS) in Patients With Primary and Secondary Central Nervous System Lymphomas (Lonca-R After SRS in CNSL)
Join now to see all

Publications & Presentations

PubMed

Cardiovascular toxicities associated with novel cellular immune therapies.
Malak Munir, Ahmed Sayed, Daniel Addison, Narendranath Epperla
Blood Advances. 2024-12-24
Transformation in marginal zone lymphoma: results from a prospective cohort and a meta-analysis of the literature.
Côme Bommier, Brian K Link, Brianna J Gysbers, Matthew J Maurer, Melissa C Larson
Blood Advances. 2024-12-10
A comparative analysis of transformed indolent lymphomas and de novo diffuse large B-cell lymphoma: a population-based cohort study.
John L Vaughn, Angela Ramdhanny, Malak Munir, Sravani Rimmalapudi, Narendranath Epperla
Blood Cancer Journal. 2024-11-29

Abstracts/Posters

Brentuximab Vedotin (BV) and Lenalidomide (Len) in Relapsed and Refractory (r/r) Cutaneous (CTCL) and Peripheral (PTCL) T-Cell Lymphomas; A Planned Interim Analysis of...
Narendranath Epperla, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Outcomes of Patients with Newly-Diagnosed Burkitt Lymphoma (BL) and Central Nervous System (CNS) Involvement Treated in the Modern Era: A Multi-Institutional Real-Worl...
Narendranath Epperla, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Clinical Trial Participation Is Associated with Improved Overall Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma
Narendranath Epperla, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Outcomes Following Early Relapse in Patients with Mantle Cell Lymphoma
Narendranath Epperla, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Maintenance Rituximab Improves Outcomes in Mantle Cell Lymphoma Patients Who Respond to Induction Therapy with Bendamustine + Rituximab without Autologous Transplant
Narendranath Epperla, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
The Evaluation and Treatment (Tx) of Burkitt Lymphoma (BL) in the Modern Era: Real World (RW) Outcomes and Prognostication across 26 US Cancer Centers (CC)
Narendranath Epperla, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Results of a Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma
Narendranath Epperla, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Impact of Novel Agents on Outcomes of Patients with Classical Hodgkin Lymphoma and Primary Treatment Failure
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019

Authored Content

Incorporating Novel Agents Into Classical Hodgkin Lymphoma TreatmentDecember 2021

Press Mentions

Incorporating Novel Agents into Classical Hodgkin Lymphoma TreatmentDecember 1st, 2021
Genomic Mutation Profile of Primary Gastrointestinal Diffuse Large B-cell LymphomaFebruary 8th, 2021